FDA Approves Immunovaccine's Application for a Phase I/II Clinical Trial for an Ovarian Cancer Vaccine
HALIFAX, NOVA SCOTIA-- - Immunovaccine Inc. , announced today that the US Food and Drug Administration reviewed and cleared its Investigational New Drug application for a Phase I/II clinical study with DPX-Survivac, a therapeutic cancer vaccine.

Biosimilar and Biomarker Approvals to Cut Costs - Research Report on Micromet, Inc. and CEL-SCI Corporation
MACAU--(Marketwire - 06/13/11) - Today, www.EquityMarketsInc.com announced its research report highlighting Micromet, Inc. (NASDAQ: MITI - News ) and CEL-SCI Corporation (AMEX: CVM - News ). Full content and research is available at www.EquityMarketsInc.com/research.php . This sector demonstrates renewed investor interest as new and lucrative ...

FDA 'Crushing' Massachusetts Biotech Business, GOP Senator Says
The U.S. Food and Drug Administration is "crushing" Massachusetts businesses that need the agency's approvals without "rhyme or reason," U.S. Sen. Scott Brown told leaders from the biotechnology industry this morning in Boston.